TAIKO PHARMACEUTICAL CO.,LTD.
4574・Prime Market・Pharmaceuticals
Business
Taiko Pharmaceutical is a pharmaceutical company founded in 1946 and originating in Osaka. In its core Pharmaceuticals Business, the company manufactures and sells over-the-counter drugs such as Seirogan and Seirogan Toui A both domestically and overseas, accounting for approximately 90% of consolidated net sales. In its Infection Control Business, the company develops the Cleverin brand, which leverages patented chlorine dioxide technology, serving a wide range of customers from individual consumers to business customers such as public institutions and medical facilities. Domestically, the company's main channels are drugstores and pharmacies, while overseas it operates primarily in Asia through its network of subsidiaries in Hong Kong, China, and Taiwan, as well as through distributors. The main active ingredient, Japanese Pharmacopoeia wood creosote, is manufactured by subsidiary Taiko TEC Co., Ltd., forming a vertically integrated supply system.
Business Model
In the Pharmaceuticals Business, highly recognized brand products such as "Seirogan" are supplied to drugstores and pharmacies via wholesalers (Alfresa Healthcare 30.0%, PALTAC 21.0%, etc.). A vertically integrated structure in which the company's own group manufactures the main active ingredient, JP wood creosote, supports cost competitiveness. The Infection Control Business deploys "Cleverin" in both BtoC and BtoB channels, sharing sales channels with the Pharmaceuticals Business to achieve efficient market penetration. Overseas, the company employs a multi-layered sales structure combining a network of subsidiaries and distributors.
Company Strengths
"Seirogan" originated in 1902 and has a sales track record spanning over 120 years. It maintains a high brand recognition rate in the domestic antidiarrheal market, and the domestic antidiarrheal market size in FY2025 (ending December 2025) grew steadily at 103.1% year on year. The Pharmaceuticals Business segment profit margin of 27.3% underpins the company's high-profitability structure.
The company has a vertically integrated structure in which its subsidiary Taiko TEC Co., Ltd. manufactures the main ingredient, Japanese Pharmacopoeia wood creosote. The relocation of production equipment for the reorganization into a two-plant system (Suita Plant and Kyoto Plant) announced in August 2024 was completed as planned during FY2025 (ending December 2025), and the full-scale operation of the pharmaceutical production line at the Kyoto Plant established a stable supply system.
The company has established subsidiaries in Hong Kong, China, and Taiwan, building a sales network across Greater China. In China, it is expanding its distribution channels from its Hong Kong base into South China, East China, North China, and Northeast China. Overseas sales in FY2025 (ending December 2025) reached ¥2,266 million (up 2.0% year on year), and the medium-term management plan also positions the strengthening of expansion in Greater China as a key strategy.
ENVALITH's Perspective
Performance Trend
Following structural reforms after a substantial operating loss in FY2021 (net sales ¥11,299 million, operating loss ¥4,947 million), the company returned to profitability in FY2024 (operating income ¥629 million), but operating income declined to ¥459 million in FY2025 due to rising costs, among other factors. In Q1 of FY2026 (ending December 2026), net sales fell to ¥916 million (down 20.4% year on year) and the company posted an operating loss of ¥98 million, a further deterioration. Domestic pharmaceutical sales were pushed down by a supply shortage of Seirogan, the resumption of supply by competing products, and a decline in inbound demand, while increased costs from strengthening the supply structure in the Pharmaceuticals Business squeezed gross profit (down 26.3% year on year to ¥500 million). In the Infection Control Business, net sales fell sharply by 64.6% year on year to ¥56 million, partly due to the external factor of the fading influenza outbreak. Total assets stood at ¥11,325 million (down ¥945 million from the end of the previous fiscal year), and the equity ratio remained at 73.0%, maintaining financial soundness.
Growth Strategy
Advancing focused investment in the Pharmaceuticals Business and global growth under the medium-term management plan (2026-2028)
For Seirogan, which continues to face supply issues, preparations for equipment upgrades and other measures aimed at shortening lead times and improving productivity from the second half of the fiscal year onward are being advanced. As of the first quarter of FY2026 (ending December 2026), preparations remain in progress, and the impact of supply shortages on domestic sales continues.
Under a policy of increasing advertising expenses compared to the previous year, the company is working on marketing initiatives aimed at the summer demand season. The first quarter is in the planning and preparation stage, with effects expected to materialize from the second quarter onward.
Due to an increase in shipment volumes to the Hong Kong and Taiwan markets, overseas pharmaceutical sales in the first quarter of FY2026 (ending December 2026) expanded significantly to ¥198 million (up 130.6% year on year). Progress is being made in strengthening a direct export base that does not depend on inbound demand.
Through effective marketing expenditure allocation and other cost control measures, the segment loss for the first quarter of FY2026 (ending December 2026) improved to ¥41 million, an improvement of ¥21 million year on year. The company also aims to increase sales through the expansion of the commercial-use (BtoB) segment.
Last updated: July 17, 2026